EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent

Significantly lower TLF rates (2.8% versus 7.8%, p=0.020) with DynamX® compared to Resolute Onyx DES with no new events in bioadaptor arm between 3 and 4 years 88% reduction in Cardiovascular Death (0 ...
MassDevice

Elixir Medical study backs DynamX bioadaptor against drug-eluting stent

Elixir Medical announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent.
Yahoo Finance

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...
Business Wire

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
EurekAlert!

DynamX Bioadaptor, a novel 'uncaging' platform for coronary artery revascularisation

Drug Eluting Stents (DES) are the mainstay of coronary artery disease treatment. Although DES design iterations have reduced MACE in the first year after PCI, beyond 1-year, a persistent 2-3% ...
Business Wire

Elixir Medical Completes Enrollment in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled ...